SunWay Biotech Co

SunWay Biotech Co Net Debt per Share

The Net Debt per Share of SunWay Biotech Co (1271.TWO) as of Oct 20, 2026 is 6.77 TWD. In the previous year, Net Debt per Share was -0.73 TWD — a change of -1,032.35% (higher).

Net Debt per Share

6.77TWD

YoY

-1,032.35%

Last updated:

Net Debt per Share of SunWay Biotech Co is 2025 6.77 TWD. Net Debt per Share of SunWay Biotech Co was 2024 -0.73 TWD. It decreases by -1,032.35% higher compared to the previous year.

The SunWay Biotech Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2019
-0.76 TWD
Jan 1, 2020
-4.61 TWD
Jan 1, 2021
-5.39 TWD
Jan 1, 2022
-0.86 TWD
Jan 1, 2023
-0.97 TWD
Jan 1, 2024
-0.73 TWD
Jan 1, 2025
6.77 TWD
The SunWay Biotech Co Net Debt per Share history
YEARNet Debt per ShareYoY
6.77TWD-1,032.35%
-0.73TWD-25.22%
-0.97TWD+12.28%
-0.86TWD-83.97%
-5.39TWD+17.01%
-4.61TWD+509.64%
-0.76TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co., Ltd. generates revenue through the research, development, manufacture, and sale of red yeast health food products. The company's main products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which target digestive health, bacterial ecology regulation, immunity, and allergy management. These products are sold in both domestic and overseas markets, catering to consumers seeking natural health solutions. The firm focuses on health food segments where digestive and immune support are key consumer needs. The company's product portfolio emphasizes specific strains like Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their functional benefits in digestion and immune regulation. These health foods are distributed across domestic and international channels, targeting health-conscious consumers who prioritize natural remedies. SunWay Biotech leverages its research-driven approach to position these products in the health food market. SunWay Biotech Co., Ltd. operates within the health food industry, focusing on products that address digestive and immune health through natural ingredients. Its offerings are designed to improve bacterial ecology in the digestive tract and regulate immunity and allergies, appealing to a segment of consumers interested in preventive health solutions. The company's domestic and overseas market strategy ensures broad reach for its specialized health food products. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SunWay Biotech Co stock

Net Debt per Share of SunWay Biotech Co is 6.77 TWD in 2025.

Net Debt per Share of SunWay Biotech Co changed from -0.73 TWD to 6.77 TWD, representing a -1,032.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — SunWay Biotech Co

All Key Metrics — SunWay Biotech Co